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Sexual dysfunctions in HIV-positive men are associated with an increase in risky sexual behavior and decreased adherence to
antiretroviral drug regimens. Because of these important public health issues, we reviewed the literature on the pathophysiology,
associated factors and clinical management of sexual dysfunction in HIV-positive men. The goal was to investigate the current
research on these issues. Literature searches were performed in June 2011 on PubMed, Web of Science, and PsycInfo databases
with the keywords “AIDS” and “sexual dysfunction” and “HIV” and “sexual dysfunction”, resulting in 54 papers. Several
researchers have investigated the factors associated with sexual dysfunction in HIV-positive men. The association between sexual
dysfunction and antiretroviral drugs, particularly protease inhibitors, has been reported in many studies. The lack of standardized
measures in many studies and the varying study designs are the main reasons that explain the controversial results. Despite some
important ﬁndings, the pathophysiology of sexual dysfunction in the HAART era still not completely understood. Clinical trials of
testosterone replacement therapy have shown the treatment to be beneﬁcial to the improvement of sexual dysfunctions related to
hypogonadism. However, there are not enough psychological intervention studies to make conclusions regarding the therapeutic
eﬀects of psychotherapy.
1.Introduction
Highly active antiretroviral therapy (HAART) has previously
been shown to provide the best clinical management for
HIV-infected patients, as it decreases the prevalence of hypo-
gonadism and advanced HIV disease, which are the principal
causes of sexual dysfunction in people infected with HIV
[1, 2]. However, the prevalence of sexual dysfunctions in the
years since the advent of highly active antiretroviral therapy
(HAART),whichvariesaccordingtotheculturalandmetho-
dological issues of the studies in question, includes high rates
of erectile dysfunction (ED) (9–74%), ejaculatory distur-
bances(36–42%),andlowsexualdesire(LSD)(24–73%)[2].
In an English clinical study conducted in 2001 with 78
HIV-positivegaymen,69%reportedoneormoresexualpro-
blems. ED was reported by 38% of the men, which rose to
51% in the context of trying to use condoms. Loss of interest
in sex was reported by 41%, and 24% experienced delayed
ejaculation [3]. From October 2002 to January 2003, a case-
controlBrazilianstudynestedinacross-sectionalpopulation
of individuals with AIDS found that almost 50% of the men
reported ejaculatory symptoms, 33% reported ED, and 12%
reported dyspareunia [4].
After receiving the diagnosis of HIV infection, it is com-
mon for people to experience negative moods and decrease
thefrequencyofsexualactivity,andthosewhoremainsexua-
lly active most likely do so without adequate protection [5].
Adherence to safe sex practices after HIV diagnosis may have
a negative impact on the sexual functioning of most subjects
[6]. Individuals who are partnered are signiﬁcantly more
likely to maintain sexual activity than those who do not have
ap a r t n e r[ 7].
Inastudywithaconveniencesampleof156HIV-positive
gay men and 155 HIV-negative gay men selected from the
community and the internet who were matched for age and
unprotected anal intercourse (UAI), the HIV-positive men2 Advances in Urology
were more likely to report ED and higher scores on the inhi-
bition of arousal due to the threat of performance failure [8].
The presence of ED associated with condom use has been re-
ported by gay men. Risk cognitions such as wanting to lose
oneself in sex, placing the responsibility for condom use to
the active partner, and perceptions that condoms interfere
withpleasureweresigniﬁcantlymorelikelytobeendorsedby
those who reported ED associated with condom use [3].
In addition, it must be considered that individuals who
acquire HIV through sexual or parenteral (excluding blood
transfusions) routes of infection are already part of a popu-
lation that is at higher risk for sexual dysfunction, as many
riskfactorsforHIVarealsolinkedtotheoccurrenceofsexual
dysfunction such as conﬂicts with one’s sexual orientation
or sexual identity, depression, and psychological problems
related to self-image [9, 10].
Moreover,sexualdysfunctionhasanimpactonthequali-
ty of life and very often leads to negative attitudes on the
partoftheindividual,includingpooradherencetoantiretro-
viral regimens and to safer sex strategies [11–13]. HIV-in-
fected people with sexual dysfunction who are nonadherent
to antiretroviral regimens have an increased risk of trans-
mission of drug-resistant strains because of higher-risk sex-
ual behavior, higher HIV RNA concentrations in semen and
cervical secretions [14], and inappropriate use of phospho-
diesterase-5 (PDE-5) inhibitors without medical recommen-
dations with higher likelihood of negative interaction with
antiretrovirals [11, 12, 15].
Because of the increases in risky sexual behavior and
decreased adherence to antiretroviral drugs reported in HIV-
positive men with sexual dysfunctions, we decided to review
the literature on the pathophysiology, associated factors, and
clinical management of sexual dysfunctions in HIV-positive
men. The goal of this review is to investigate the current
research on these issues.
2. Methods
Literature searches were performed in June 2011 on the Pub-
Med, Web of Science, and PsycInfo databases with the key-
words“AIDS”and“sexualdysfunction,”whichresultedin36,
11, and 21 articles, respectively. These searches were also per-
formed with the keywords “HIV” and “sexual dysfunction,”
which resulted in 56, 12, and 22 articles, respectively. The
abstracts were reviewed and the inclusion criteria required
thatthestudieswereclinicalstudiesontheassociatedfactors,
pathophysiology, and clinical management of the sexual dys-
functions of HIV-positive men, and that they were publish-
ed in English. Posters and abstracts of presentations in con-
gress or scientiﬁc meetings were excluded from our search.
Firstly, 20 studies were included and reviewed. After search-
ing the reference lists of these papers, 34 more studies were
reviewed, resulting in a total of 54 papers.
3. Results
Fifty-four papers on the associated factors, pathophysiology,
and clinical management of sexual dysfunction in HIV-
positive males were reviewed.
3.1. Associated Factors. There are four important factors
associated with sexual dysfunction in HIV/AIDS patients:
mental, hormonal, pharmacological, and other morbid con-
ditions. Table 1 lists the studies on these associated factors.
3.1.1. Mental Factors. A representative French study on
1,812 HIV outpatients who were being treated for HIV
and reported having had at least one sexual partner in
the 12 months prior to the survey showed an association
between sexual diﬃculties and knowing more than four
people who lives with HIV/AIDS, perceiving side eﬀects as
very disturbing, reporting lipodystrophy-related symptoms
and having a high HIV-discrimination score in the prior
12 months. Moreover, CD4 cell levels, viral load titers, and
CDC stage, and current HAART treatment at the time
of the study were not associated with sexual diﬃculties.
The authors recommended psychological support for HIV
patients in order to improve the sexual aspects of their
lives [17]. Feelings of guilt from having acquired HIV via
sexual transmission may be a mental factor that negatively
inﬂuences the sexual response. This psychological factor may
explain some reports of higher rates of sexual dysfunctions
in homosexual and bisexual men [26, 27].
Depression is one of the most important mental factors
associated with sexual dysfunctions [28]. A study on 300
HIV-infected men found that older age and depression
were associated positively with ED, and higher CD4 cell
counts were associated negatively, then, and higher CD4 was
considered protective regarding ED [18].
3.1.2. Hormonal Factors. Hypogonadism was one of the
most frequent causes of sexual dysfunction before HAART.
Currently, HIV-infected individuals may have higher testos-
terone levels than noninfected individuals.
The prevalence of hypogonadism has been lowered with
the introduction of HAART, but it still remains the most
common endocrine disorder of HIV-infected men [29].
Moreover, estradiol is often higher in men (50% of
them) on HAART, possibly due to augmented peripheral
conversion of androgens to estrogens in lipid tissues [30,
31]. However, the role of estradiol in HIV-related sexual
dysfunctions is not clear. The expected decreased levels of
gonadotropin hormones in the blood were not observed
[24], and one study observed improved sexual function
despite higher blood levels of estradiol [23]. Hyperpro-
lactinemia may be associated with sexual dysfunction as it
decreases the release of gonadotropins and has been found
in some HIV-positive individuals. However, one study found
no diﬀerence in prolactin levels between patients with and
without sexual diﬃculties [23].
3.1.3. Pharmacological Factors. Table 1 lists the studies on
the association between antiretrovirals, particularly protease
inhibitors, and sexual dysfunction.
Ejaculatory dysfunction has been shown to be associated
with the use of didanosine [9] as well. Moreover, HIV-
infected individuals use many other medications that are
associatedwithdecreasedsexualresponses.MedicationssuchAdvances in Urology 3
Table 1: Associated factors studies.
Study Population Method Results
Mao et al. 2009
[16]
542 gay men, 40% of
whom were HIV+
Cross-sectional.
Nonstandardized instrument was used
In HIV+ men SD was associated with
avoidant strategies to cope with daily life
stress, sexual risk-taking in casual
encounters, and use of antidepressants
Trotta et al. 2008
[12]
612 HIV+ outpatients
using HAART of
whom 72% were men
Intercohort analysis 2 Italian cohort
studies (AdICoNA; AdeSpall).
Global Health Status (GHS) was used
SD associated with suboptimal HAART
adherence and self-reported worsening of
viro-immunological parameters
Bouhnik et al.
2008 [17]
1,812 HIV+
outpatients (40.6%
homosexual men,
24.4% women)
National cross-sectional survey.
Nonstandardized instruments were used
Sexual diﬃculties were associated with
discrimination, suﬀering from
lipodystrophy, very disturbing
HIV-related symptoms, but were not
with HAART
Crum-Cianﬂone
et al. 2007 [18]
300 HIV+ male
outpatients
Cross-sectional study. International IIEF,
Androgen Deﬁciency in Aging Men
(ADAM Questionnaire) Beck Depression
Inventory
ED was associated with older age and
depression, not HAART and
hypogonadism. Current higher CD4
account was protective against ED.
Asboe et al. 2007
[19]
668 HIV+ male
outpatients
Prevalence and associated factors study.
Clinical data collected by interview and
case review.
International Index of Erectile Function
(IIEF) was used.
ED: older age, heterosexual, nonalcohol
use, depression, antidepressants,
psychotropic, and duration of HAART.
LSD: older age, depression, and black
African ethnicity
Guaraldi et al.
2007 [20]
336 HIV+ male
outpatients
Cross-sectional study.
Prevalence and associated factors were
investigated.
IIEF was used.
Testosterone level was checked
ED was independently associated with
body mass index. Desire, orgasm and
satisfaction were associated with mental
health scores. Testosterone, metabolic
alterations, and HAART were not
associated with SD
Richardson et al.
2006 [21]
190 HIV+ male
outpatients
Retrospective notes on risk factors to SD
written last 18 months.
Nonstandardized instruments were used
Retarded ejaculation was associated with
peripheral neuropathy
Cove and Petrak,
2004 [3]
78 HIV+ male
outpatients
Cross-sectional study.
Prevalence and associated factors were
investigated.
Hospital Anxiety and Depression Scale
(HADS).
Risk cognitions such as wanting to lose
oneself in sex and leaving responsibility
for condom use to the active partner were
associated with ED related to condom
use, and low T-cell count (<200) was
associated with sexual problems
Lamba et al.
2004 [22]
73 HIV+ male (88%
MSM) and 100 HIV-
MSM
Prospective study.
Non-standardized instrument was used
Increased estradiol serum levels and LSD
were associated with HAART
Collazos et al.
2002 [23]
189 HIV+ clinically
stable outpatient
males using
antiretrovirals
Prospective study.
Nonstandardized instruments were used
Only antiretrovirals remained associated
to SD after logistic regression.
Hypogonadism was not associated
Collazos et al.
2002b [24]
189 HIV+ clinically
stable outpatient
males using
antiretrovirals
Prospective study.
Nonstandardized instruments were used
HAART was associated with increased
levels of both testosterone (more with PI)
and 17beta-estradiol (more with
nonnucleoside reverse transcriptase
inhibitors)
Schrooten et al.
2001 [25]
720 male and 184
female HIV+
outpatients
Multicentric cross-sectional study.
Anonymous questionnaire.
Nonstandardized instruments were used
LSD was associated with protease
inhibitors current and past, symptomatic
HIV infection, age, and homosexual HIV
transmission mode. ED was associated
with protease inhibitors, symptomatic
HIV, age and tranquilizers
Sollima et al.
2001 [26]
334 HIV+ male
outpatients
Cross-sectional study.
Beck depression inventory
ED was associated with homosexuality,
CD4 cell count, viral load, and indinavir.
Protease inhibitors were associated with
peripheral neuropathy causing ED4 Advances in Urology
Table 1: Continued.
Study Population Method Results
Catalan and
Meadows, 2000
[27]
34 gay and bisexual
men HIV+
outpatients
Cross-sectional study.
Nonstandardized instrument was used
Psychogenic ED associated with nonuse
of antiretrovirals
Newshan et al.
1998 [6]
50 HIV+ male
outpatients
Cross-sectional study.
Derogatis Sexual Functioning Inventory
was used
Sexual dissatisfaction was associated with
symptomatic HIV/AIDS
Note: SD = sexual dysfunctions.
as ketoconazole, ﬂuconazole, ganciclovir, megestrol, metha-
done, and cimetidine may decrease testosterone levels and
cause sexual dysfunction [6, 32]. Antihypertensives, diure-
tics, hypolipemics, benzodiazepines, antidepressants, and
antipsychotics are also associated with sexual dysfunctions
[19, 32–34].
3.1.4. Comorbid Conditions. Some morbid conditions are
common in HIV-infected individuals and some of them are
often associated with sexual dysfunction, such as hepatopa-
thy, diabetes, hyperlipidemia, hypertension, vascular disease,
and alcohol dependence [35].
Peripheral neuropathy is a well-documented compli-
cation of both HIV infection by direct viral toxicity and
HAART, most notably with thymidine analog nucleoside re-
verse transcriptase inhibitors. There is a signiﬁcant associ-
ation in HIV-positive men between peripheral neuropathy
and delayed ejaculation [21].
Another study on 12 patients with ED reported neuropa-
thyofthesacralregionwasassociatedwithproteaseinhibitor
use, particularly indinavir [26].
3.2. Pathophysiological Issues. One prospective, age- and sex-
matched study in Nairobi on 25 patients (7 with asympto-
matic HIV, 8 with AIDS-related complex, and 10 with AIDS)
and 25 controls was evaluated for its autonomic functioning.
Substantial autonomic dysfunctions were seen in AIDS pa-
tients relative to controls, and mild abnormalities in the
majorityofHIV-infectedpatientswerefound[36].Thisﬁnd-
ingcouldexplaintheassociationbetweendelayedejaculation
and peripheral neuropathy [30] .Th ep h y s i o l ogi c a lp r oc e s so f
ejaculation is under autonomic control via the hypogastric
(sympathetic) and pudendal (parasympathetic) nerves [30].
Another relevant point regarding the pathophysiology
of the sexual dysfunctions of this population is that many
patients who are on HAART to treat their HIV infection
andhavelipodystrophyalsohaveelevatedestrogenlevelsand
complain of low sexual desire. As a possible pathological
mechanism, one can consider an increase in the number of
ﬁbroblasts and macrophages present in lipoatrophic areas
that could convert testosterone to estrogen by intracellular
aromatization. This process is known to be enhanced by
increased levels of tumor necrosis factor, interleukin 6 (IL-
6), and hydroxycorticosteroids present in many patients with
HIV lipodystrophy [31].
In addition, a study on rabbits found estrogen receptors
in the cavernous body of the penis and found pathophysio-
logical changes in erectile function when rabbits were treated
with continuous estrogen [37] .A n o t h e rs t u d yo fo l d e rm e n
found that the balance between testosterone (decreased) and
estradiol (increased) is associated with ED [38].
Anecdotal reports suggest an association between pro-
tease inhibitor use and sexual dysfunctions, but only a few
studies have found speciﬁc evidence for the link. These
studies found a possible eﬀect of the protease inhibitors on
the binding of the steroids hormones with their receptors
[39] or causing the blockade of androgen receptor [40], both
actions could be related to sexual diﬃculties associated with
protease inhibitors.
3.3. Clinical Management. The clinical management of
sexual dysfunctions in HIV/AIDS patients involves clinical
assessment, pharmacotherapy, psychotherapy, and psychoe-
ducational approaches to safer sex. Table 2 lists the clinical
management studies.
3.3.1. Clinical Assessment. In order to investigate the sexual
functioning of HIV-infected people, the ﬁrst point to con-
sider is ensuring an appropriate doctor-patient relationship
[46]. It is important that professionals maintain an open-
minded attitude and be free of judgments.
Clinical History. The clinical history contains the assess-
ment of the patient’s immunological conditions, comor-
bidities, and medications. Severe immunological damage
may indicate an AIDS diagnosis. Poor health undermines
the overall physical condition and the sexual response.
Nevertheless, hypogonadism should be investigated. Upon
physical examination, gynecomastia and testicular atrophy
may indicate hypogonadism [47]. Hypogonadism is deﬁned
by low levels of testosterone (<300nh/dL) in the early
morning, with associated clinical manifestations, including
sexual dysfunction, weight and muscle mass loss, fatigue,
depressed mood, and anemia [29].
SexualHistory. Whensexualityisrepressed,itcanbediﬃcult
forindividualstofullyexperiencesexandloveinadolescence
andyoungadultlife[48].Theseexperiencesarefundamental
to the sexual maturation process. When it fails because of
sexual repression and possible internal conﬂicts regarding
living the sexuality experience, it can undermine the sexual
response. Other factors in an individual sexual history mayAdvances in Urology 5
Table 2: Clinical management studies.
Study Population Method Results
Wasserman
et al., 2008
[66]
3 HIV+ male with ED, decreased
morning erections, and libido,
wasting syndrome, and
hypogonadism
Case report.
All presented low testosterone and SHBG
serum levels while using oxandrolone and
testosterone
After discontinuing oxandrolone one
showed improved libido and ED and all
showed improved testosterone and SHBG
Richardson
et al., 2007
[70]
1 3M S MH I V +o nH A A R Tw i t h
LSD and estradiol levels
>120pmol/L
Subjects were randomly allocated to
receive testosterone (N = 6) or letrozole
(N = 7) for 6 weeks.
Spector Sexual Desire Inventory (SSDI),
Depression/Anxiety Stress Scale (DASS)
were used
Desire and mean sexual acts improved in
both treatment arms.
Luteinizing hormone and testosterone
increased in all men on letrozole
Schrader et al.,
2005 [42]
48 HIV+ males with decreased
testosterone levels, libido, and
sexual functioning
Multicenter randomized controlled trial.
Testim gel was used by 24 men after 2
weeks using AndroGel. Brief male sexual
function inventory (BMSFI) was used
Experimental group improved in 4 of 5
domains (sexual drive, erectile function,
problem assessment, and sexual
satisfaction) of BMSFI (P<0.05)
Catalan and
Meadows,
2000 [27]
34 gay and bisexual men HIV+ Cross-sectional study.
Nonstandardized instrument was used
Cognitive behavioral therapy, alprostadil,
and sildenaﬁl.76% resolved the problem
and 14% improved, particularly with
physical therapy
Rabkin et al.,
2000 [69] 74 HIV+ male outpatients
Double-blind, placebo-controlled 6-week
trial with biweekly testosterone
injections, followed by 12 weeks.
Clinical Global Impressions Scale (CGIS)
was used
Testosterone group improved more on
libido and energy than placebo group
(P<0.05). Parameters were kept by 18
weeks
Wagner and
Rabkin, 1998
[45]
23 AIDS eugonadal men with
hypogonadism symptoms
Intervention study of 12 weeks of
biweekly intramuscular injections of
testosterone cypionate CGIS was used
Majority of the 19 subjects who
completed the trial showed improvement
of SD and other hypogonadism
symptoms
Note: AndroGel is a registered trademark of Solvay Pharmaceuticals, Inc., Marietta, Georgia, USA, and Testim is a registered trademark of Auxilium
Pharmaceuticals, Inc., Norristown, Pennsylvania, USA. MSM: Men who have sex with men. SD: sexual dysfunctions.
be relevant to their experience of sexual dysfunction like
sexual violence suﬀered during childhood and adolescence,
whichcanalsoleadtoseriouspsychologicaleﬀectsandsexual
consequences [48–50].
An individual’s ﬁrst sexual experiences with boys or girls,
his/her ﬁrst complete sexual relationship, and masturbation
are all signiﬁcant steps in the sexual maturation process,
which involves gaining knowledge about one’s body (eroge-
nous zones) and of the bodies of others. When a person
has sexual diﬃculties in their early sexual experiences that
they are not prepared to deal with, these experiences can
promote a negative attitude regarding sex; new experi-
ences will be avoided, thus undermining sexual maturation
[51].
A person with sexual inexperience is at higher risk for
sexual dysfunction [51], and, in turn, a person with sexual
dysfunction is at higher risk for unsafe sexual behavior [47],
even if infected by HIV.
Some speciﬁc gender issues are also important and
should be investigated. For men, homosexual orientation
presents a special vulnerability for sexual dysfunction, per-
haps because of the process of accepting sexual orientation,
the diﬃculties in dealing with poor acceptance by family
and society, and problems with gender identity [52]. Some
studies have reported higher rates of sexual dysfunction in
HIV-infected men who have sex with men [3].
Table 3: Clinical diﬀerences between organic and psychogenic
sexual dysfunction.
Characteristics Organic Psychogenic
Age of onset Older Younger
Onset Insidious Quick
Pattern Constant Variable
Masturbation Yes No
Adverse life events and/or problems
on the onset of sex life No Yes
Men: penile nocturnal
Erection No Yes
Characteristics of Organic or Psychogenic Sexual Dysfunctions.
It is also relevant to distinguish between characteristics of
organic or psychogenic sexual dysfunction (Table 3)[ 23, 53–
55].ConsideringHIVinfection,wecouldconcludethatindi-
viduals who are seropositive but are in good health probably
have sexual dysfunctions due to a psychogenic etiology, and
individuals with poor immunological conditions or an AIDS
diagnosis probably have sexual dysfunctions that are due to
organic factors.
Measures. Some standardized instruments for the quick
assessment of sexual responses can be used, as health6 Advances in Urology
practitioners often ﬁnd it diﬃcult to investigate the sex lives
of their patients. For males, there is the International Index
of Erectile Function (IIEF), which addresses the relevant
domains of male sexual function (erectile function, orgasmic
function, sexual desire, intercourse satisfaction, and overall
satisfaction). This instrument is psychometrically tested and
readily self-administered in research or clinical settings [56].
LaboratoryAssessment. Laboratory assessment may involve a
screening of sexual hormones including testosterone, estro-
gen, estradiol, prolactin, and gonadotropin. It is important
to check the serum-free testosterone level or the levels
of sex-hormone-binding globulin because they are usually
increased in HIV-infected individuals [57]. Preliminary
evaluations can be accomplished by determining the free
testosterone level because the total level may be falsely
reassuring due to an elevation in sex-hormone-binding
globulin, the principal binding protein for testosterone [29].
Whenorganicetiologyissuspected,morecomprehensive
evaluations can take place, such as Doppler ultrasonography
to assess possible arterial obstruction or nerve conduction
studies to assess possible cases of neuropathy.
3.3.2. Pharmacotherapy
Antiretrovirals. All antiretroviral drugs are associated with
diﬀerent degrees of sexual dysfunction. The highest rates of
dysfunctionareassociatedwithindinavirandthelowestwith
nevirapine [58].
If medication is the principal factor leading to sexual
dysfunction, one can try another drug that has less inﬂuence
on sexual response, such as nevirapine [2, 58] or atazanavir
[59].
Phosphodiesterase-5 Inhibitors. The use of PE-5 inhibitors
is highly recommended in male sexual dysfunction [55],
but one should be careful of drug interactions with
antiretro-virals, particularly with protease inhibitors (espe-
cially ritonavir), the nonnucleoside reverse transcriptase
inhibitor dela-virdine, and ketoconazole. Because all of these
drugs are metabolized by the cytochrome P-450 system,
the dosages of PE-5 inhibitors should be reduced [47, 60].
In this situation, the recommended dosage of sildenaﬁl is
25mg every 48 hours (also reduced to 2.5mg every 72
hours when also using ritonavir), of vardenaﬁl is 2.5mg
every 24 hours, and of tadalaﬁl is 10mg every 72 hours
[60–63].
Pharmacokinetic studies have demonstrated that silde-
naﬁl does not increase the blood levels of protease inhibitors,
but indinavir, saquinavir, and ritonavir [60, 63] signiﬁcantly
increase sildenaﬁl levels. There is, therefore, a risk of drug
interaction between sildenaﬁl and protease inhibitors, lead-
ing to hypotension and possible death in one case [64].
PE-5 inhibitors with longer half-lives may increase the
risk of adverse eﬀects for longer periods of time when com-
bined with protease inhibitors. The use of sildenaﬁl may be
preferred because of its shorter half-life [29].
Poppers (amyl nitrate) are contraindicated by male
users of PE-5 inhibitors because they lower blood pressure,
especially in combination with PE-5 inhibitors [65].
Testosterone Replacement. If the patient meets the diagnos-
ticcriteriaforhypogonadism,therearesomeoptionsfortest-
osterone replacement. Multiple formulations exist, ranging
from intramuscular to transdermal and buccal admin-
istration. The latter avoids ﬁrst-pass metabolism and results
in more sustained serum testosterone concentrations [29].
Testosterone replacement is not prescribed for HIV
patients without observed decreases in free testosterone
bloodlevelsbecausenoimprovementsofsexualdysfunctions
have been reported in this condition and the risks of treat-
ment do not outweigh the beneﬁts [2]. Testosterone replace-
ment therapy can sometimes be problematic even in hypo-
gonadal males. One study reported three HIV-infected
patients with ED who presented low testosterone and sex-
hormone-binding globulin (SHBG) despite receiving long-
term oxandrolone in addition to testosterone replacement
therapy and HAART.
Discontinuation of oxandrolone led to the normalization
or improvement of testosterone levels in all three patients,
with symptomatic improvement in one patient. The authors
hypothesized that the ﬁrst-pass metabolism of orally admin-
istered oxandrolone may decrease the hepatic synthesis of
SHBG, allowing exogenously supplied testosterone to be
excreted [41].
In addition, testosterone replacement shows good results
in improving the sexual dysfunction of most of hypogonadal
HIV-infected individuals [44, 66–69]. The use of a topical
testosterone gel [43] was shown to improve sexual function
and also caused heightened erythropoiesis, weight gain,
prevention of bone loss, increased energy, and improved
mood [29].
Letrozole. Finally, some improvement in sexual desire has
been reported in a few patients on HAART who were treated
with letrozole, an aromatase inhibitor that inhibits the
conversion of testosterone to estradiol. Thirteen men who
have sex with men who were on HAART with LSD and also
had raised estradiol levels were randomly selected to receive
either parenteral testosterone or letrozole for six weeks.
Standardized instruments demonstrated improvements in
desire and the frequency of sexual acts in both treatment
arms [42].
3.3.3. Psychotherapy. The psychotherapeutic approaches for
the treatment of sexual dysfunction of HIV-infected people
involve supportive and psychosexual therapy.
Supportive. If the most relevant factor leading to sexual
dysfunction is psychogenic, one can use supportive therapy
in the period immediately after HIV diagnosis. Therapy
should focus on demystifying the stigmas associated with
HIV/AIDS as a lethal disease that is associated with non-
conventional sexual behavior. The supportive approachAdvances in Urology 7
would diminish fear and guilt and help individuals deal with
discrimination [17].
Psychosexual. Psychosexual therapy such as sensate focus or
masturbatorytrainingisindicatedwhentheindividual’sHIV
seropositivity has already been accepted psychologically but
sexual dysfunctions still remain. The approach is the same
as that used for nonHIV-infected individuals with sexual
dysfunctions.
3.3.4. Psychoeducational Approach to Safer Sex. A psychoe-
ducational approach to safer sex is oﬀered concomitant
with the treatment of the sexual dysfunction. The approach
always involves the patient and his or her partner. Safer sex
counseling is fundamental for explaining the risks associated
with contact with diﬀerent strains of HIV, which favors the
development of the resistance to antiretrovirals.
Finally, a psychoeducational approach should encourage
lifestylemodiﬁcationsincludingsafersex,exercise,modiﬁca-
tions of cardiovascular risk factors, and education about the
eﬀects of recreational drug use [47].
An essential part of managing sexual dysfunction in
HIV patients is counseling about maintaining safer sexual
practices to minimize the risk of acquiring other sexually
transmitted infections and transmitting HIV to others. It
mustbeemphasizedthathavinganundetectableplasmaHIV
viral load does not mean that an individual is no longer able
to pass on the virus.
There is good evidence that the HIV viral load in seminal
ﬂuid is independent of plasma HIV-1 RNA levels [70].
Even if intercourse occurs between HIV-positive concordant
partners, the risks of sexual infections, transmission of drug-
resistant HIV, and superinfection remain [70].
4. Discussion
AsTable 1 shows,most(12/15)oftheclinicalstudiesonHIV-
positive male sexual dysfunctions took place from 1998 to
2007. The majority (11/15) addressed the role of HAART or
hormonalchangesinthesexualdysfunctionsofHIV-positive
men.
Ap o s s i b l er o l eo fa n t i r e t r o v i r a ld r u g si nt h eg e n e r a t i o n
of sexual dysfunction is controversial. Whereas some studies
have supported a role of antiretroviral therapy in sexual
dysfunction [19, 23, 71], other studies have not found
such an association [3, 18, 72]. In the HAART era, there
are high rates of sexual dysfunction despite general health
improvements.
Diﬀerent methodological designs and the use or lack of
standardized instruments are responsible for the controver-
sial results regarding a possible association between sexual
dysfunction and antiretrovirals. Just 4 of 15 studies (Table 1)
used standardized measures in their evaluations of sexual
dysfunctions. The diﬀerent methodologies likely contribute
to the varying results.
In contrast to depression, which was addressed by most
of the studies, other psychogenic factors were not often
investigated (Table 1).
In Table 2, we can see the scarcity of studies on the
psychological interventions for sexual dysfunctions in HIV-
positive individuals that aim to investigate the evidence for
the clinical management of psychogenic sexual dysfunctions.
Just one of the six studies addressed psychological treatment.
Curiously, this study reported that the majority of the 34
HIV-positive homosexual men experienced an improvement
of their sexual function. The problems were solved for 16
(76%) and improved for 3 (14%), whereas only 2 (10%)
reported no change. However, the physical methods of treat-
ment were more eﬀective than psychological interventions
[27] in this population.
Sexual functioning before HIV diagnosis, current physi-
cal and mental health, and psychosocial support are impor-
tant factors for improving the sexual response. A medical
team that is up to date on human sexuality is necessary for
the diagnosis and treatment of sexual dysfunctions. When
these conditions are preserved, the therapeutic results are
good [41–43].
The problem is that it is often the case that sexual
issues are not fully investigated by health professionals and
few patients will talk about sexual problems spontaneously.
As sexual dysfunctions are so prevalent in the general
population and in people living with HIV, a lot of them, have
not received medical care on their sexual diﬃculties.
Another important point in the successful diagnosis and
treatment of sexual dysfunctions lies in the scarcity of health
professionals with expertise in human sexuality. A private
issue such as this one needs professionals with the ability to
address these sensitive issues with their patients. Otherwise,
patients are not likely to disclose their sexual problems to
their doctors. When a patient receives medical care on them
sexual diﬃculties, they feels valued and will be more open
to engage in adherence to both medications and safer sex
strategies.
5. Conclusions
Sexual dysfunctions of HIV-positive men are well docu-
mented. Several researchers have investigated factors asso-
ciated with sexual dysfunction in this population. The
association between sexual dysfunction and antiretrovirals,
particularly protease inhibitors, has been reported in many
studies. Some important ﬁndings have contributed to under-
standing the pathophysiological issues associated with sexual
dysfunction, but it is still unclear how antiretrovirals cause
sexual dysfunctions. The clinical trials show that testosterone
replacementisbeneﬁcialintermsofsexualfunctioning.With
regard to psychological interventions, there are not enough
studies to provide any evidence of a therapeutic eﬀect.
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